PD 142893, SB 209670, and BQ 788 selectively antagonize vascular endothelial versus vascular smooth muscle ET(B)-receptor activity in the rat

Journal of Cardiovascular Pharmacology

Volumn 32, Issue 6, 1998, Pages 935-943

  Schroeder, Richard L ^a   Keiser, Joan A ^a   Cheng, Xue Min ^a   Haleen, Stephen J ^a  

^a PFIZER INC   (United States)

Author keywords

Endothelin antagonists; Endothelin receptors Vascular endothelial ET(B) receptor; Receptor subtypes; Vascular smooth muscle ET(B)receptor

Indexed keywords

3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; ENDOTHELIN RECEPTOR; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; PD 142983; SARAFOTOXIN S6C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENCY; DRUG SELECTIVITY; KIDNEY PERFUSION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RAT; VASCULAR ENDOTHELIUM;

EID: 0031647397     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199812000-00010     Document Type: Article

References (21)

1. Takeshi S, Yanagisawa M, Masaki T. Molecular characterization of endothelin receptors. Trends Pharmacol Sci 1992;13:103-8.
2. Panek RL, Major TC, Hingorani GP, Doherty AM, Taylor DG, Rapundalo ST. Endothelin and structurally related analogs distinguish between endothelin receptor subtypes. Biochem Biophys Res Commun 1992;183:566-71.
3. Takayanagi R, Kitazumi K, Takasaki C, et al. Presence of non-selective type of endothelin receptor on vascular endothelium and its linkage to vasodilation. FEBS Lett 1991;282:103-6.
4. Warner TD, Allcock GH, Corder R, Vane JR. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptor mediating smooth muscle contraction and the release of EDRF. Br J Pharmacol 1993;110:777-82.
5. Clozel M, Volker B, Gray GA, et al. Pharmacological characterization of bosentan: a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994;270:228-35.
6. Ohlstein EH, Nambi P, Douglas SA., et al. SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci USA 1994;91:8052-6.
7. Ishikawa K, Ihara M, Noguchi K, et al. Biochemical and pharmacological profile of a potent and selective endothelin B- receptor antagonist. BQ-788. Proc Natl Acad Sci USA 1994;91:4892-6.
8. Williams DL, Jones KL, Pettibone DJ, Lis EV, Clineschmidt BV. Sarafotoxin S6c: an agonist which distinguishes between endothelin receptor subtypes. Biochem Biophys Res Commun 1991;175:556-61.
9. B receptors mediate vasoconstriction and prostanoid release in the isolated kidney of the rat. Eur J Pharmacol 1993b;250:447-53.
10. Wu-Wong JR, Chiou WJ, Hoffman DJ, Winn M, von Geldern TW, Opgenorth TJ. Endothelins and endothelin receptor antagonists: binding to plasma proteins. Life Sci 1996;58:1839-47.
11. Dominque S, Billing A, Krieger J-P, et al. Endothelium-dependent relaxation in the isolated rat kidney: impairment by cyclosporin A. J Cardiovasc Pharmacol 1995;26:859-68.
12. Douglas SA, Hiley CR. Endothelium-dependent vascular activities of endothelin-like peptides in the isolated superior mesenteric arterial bed of the rat. Br J Pharmacol 1990;101:81-8.
13. Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists. Br J Pharmacol 1959;14:48-58.
14. Hubert JJ, Bohidar NR, Peace KE. In: Peace KE. ed. Assessment of pharmacological activity. Biopharmaceutical statistics for drug development. New York: Marcel Dekker, 1988:120-4.
15. Le Monnier de Gouville AC., Lippton H, Cohen G, Icilio C, Hyman A. Vasodilator activity of endothelin-1 and endothelin-3: rapid development of cross-tachyphylaxis and dependence on the rate of endothelin administration. J Pharmacol Exp Ther 1990; 254:1024-8.
16. Takanari K, Heistad D, Faraci F. Dilatation of the basilar artery in response to selective activation of endothelin B receptors in vivo. J Pharmacol Exp Ther 1995;273:1-6.
17. Doherty AM, Cody WL, He JX, et al. In vitro and in vivo studies with a series of hexapeptide endothelin antagonists. J Cardiovasc Pharmacol 1993;23(suppl 8):S98-102.
18. B) receptors in rabbit isolated pulmonary artery and bronchus. Br J Pharmacol 1996;118:1209-17.
19. Flynn MA, Haleen SJ, Welch KM, Reynolds EE. Endothelin B receptors on human endothelial cells and smooth muscle cells are pharmacologically equivalent. J Cardiovasc Pharmacol 1998; 32:106-16.
20. Reynolds EE, Hwang O, Flynn MA, et al. Pharmacological differences between rat and human endothelin B receptors. Biochem Biophys Res Commun 1995;209:506-12.
21. Mizuguchi T, Nishiyama M, Moroi K, et al. Analysis of two pharmacologically predicted endothelin B receptor subtypes by using the endothelin B receptor gene knockout mouse. Br J Pharmacol 1997;120:1427-30.